<DOC>
	<DOCNO>NCT01534754</DOCNO>
	<brief_summary>This multi-centre , randomise , double blind , double-dummy , parallel group , placebo-controlled trial conduct population patient suffer symptomatic uncomplicated diverticular disease order investigate best treatment prevent relapse disease . Patients randomly divide double-blind fashion one follow group : Group A . Active mesalazine 800 mg , 2 tablets/day 10 days/month plus Lactobacillus casei placebo , 1 sachet/day 10 days/month ; Group B . Active Lactobacillus casei , 1 sachet/day 10 days/month plus mesalazine 800 placebo , 2 tablets/day 10 days/month ; Group C. Active mesalazine 800 ng , 2 tablets/day plus Active Lactobacillus casei , 1 sachet/day 10 days/month ; Group D. Mesalazine 800 mg placebo , 2 tablets/day Lactobacillus casei placebo , 1 sachet/day 10 days/month . The main objective ass safety efficacy mesalazine and/or Lactobacillus casei maintain remission symptomatic uncomplicated diverticular disease</brief_summary>
	<brief_title>Mesalazine and/or Lactobacillus Casei Diverticular Disease Colon</brief_title>
	<detailed_description />
	<mesh_term>Diverticulum</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>diagnosis diverticular disease diagnose first time establish previous colonoscopy symptomatic episode uncomplicated diverticular disease 4 week prior study entry patient give free informed consent . acute diverticulitis ( complicate uncomplicated ) diverticular colitis active recent peptic ulcer chronic renal insufficiency allergy salicylates patient intend ascertained pregnancy , lactation woman childbearing age use contraceptive lactuloselactitol use two week enrolment study presence diverticulitis complication ( fistula , abscess , and/or stenosis ) use probiotic preparation either prescribe overthe counter within two week prior study entry inability give valid inform consent properly follow protocol patient active malignancy type , history malignancy ( patient history malignancy surgically remove evidence recurrence least five year study enrolment also acceptable ) recent history suspicion alcohol abuse drug addiction severe pathology interfere treatment clinical instrumental test trial use NSAIDS one week throughout study period ( paracetamol permit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>